Predicting outcomes for pregnant women with aplastic anemia
Part of Blood & lymphatic clinical trials.
This trial is testing a way to predict outcomes for pregnant women who have aplastic anemia, a condition where the bone marrow doesn't make enough blood cells. The goal is to help doctors and patients better manage the pregnancy and plan for the baby's delivery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be pregnant and have aplastic anemia, either diagnosed before or during this pregnancy.
- You must be 20 years or older.
- You must have had coagulation (clotting) blood tests done.
- You must not have ended a pregnancy before 20 weeks.
- You must be pregnant with only one baby (not twins or more).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses past patient information and early pregnancy blood test results to create a computer model that can forecast whether a fertility treatment will lead to a live birth. If you have undergone fertility treatment and had a positive early pregnancy test, your data may help improve predictions for future patients.
This study looks at health data from pregnant women to find patterns that could help predict and catch health problems in mothers and babies early. It might offer better monitoring and care during and after pregnancy.
This study looks for factors that may predict how pregnancy turns out in people with lupus (SLE) and/or antiphospholipid syndrome (APS). It may help doctors better understand what to monitor in early pregnancy to support healthier outcomes.
This study looks for blood markers that may predict whether low-dose aspirin will “work” to prevent preeclampsia in a next pregnancy. It may help improve which patients benefit most from aspirin and guide safer prevention in future pregnancies.
This study is looking at pregnancy outcomes in people who are pregnant and either have antiphospholipid antibody syndrome (APS) or do not have APS but do have prior full-term pregnancies. It may help doctors understand risks and how to manage pregnancies in these groups.
This study tests an artificial intelligence (AI) tool that tries to predict whether embryos are healthy (have the right number of chromosomes) without having to take a sample from them. If it works, it could make embryo testing less invasive and help you choose the best embryo for transfer.
Hear when a new Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.